Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
Authors:
- Anastasya Svyatoslavovna BorovkovaABAnastasya Svyatoslavovna Borovkova
- Olesya Vladimirovna PainaOPOlesya Vladimirovna Paina
- Elena Vladimirovna SemenovaESElena Vladimirovna Semenova
- Tatiana Alexandrovna BykovaTBTatiana Alexandrovna Bykova
- Anna Alekseevna OsipovaAOAnna Alekseevna Osipova
- Olga Alexandrovna SlesarchukOSOlga Alexandrovna Slesarchuk
- Polina Valerievna KozhokarPKPolina Valerievna Kozhokar
- Lubov Alexandrovna TsvetkovaLTLubov Alexandrovna Tsvetkova
- Zhemal Zarifovna RakhmanovaZRZhemal Zarifovna Rakhmanova
- Andrei Vadimovich KozlovAKAndrei Vadimovich Kozlov
- Alexei Borisovich ChukhlovinACAlexei Borisovich Chukhlovin
- Ilya Viktorovich KazantsevIKIlya Viktorovich Kazantsev
- 3 November 2023
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15181
Abstract
Introduction: The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.Methods: A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone (n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite (n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil (n = 42, 66.7%) or PTCy+CNI+sirolimus (n = 12, 19%). All patients (n = 69) in the control group received ATG+CNI+antimetabolite.Results: After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.Conclusions: In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.Keywords
This publication has 34 references indexed in Scilit:
- Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilTransplantation and Cellular Therapy, 2016
- Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantationBlood, 2016
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic MalignanciesTransplantation and Cellular Therapy, 2016
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease ProphylaxisTransplantation and Cellular Therapy, 2013
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseBlood, 2010
- 6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT)Transplantation and Cellular Therapy, 2007
- THE EFFECT OF CYTOTOXIC DRUGS ON GRAFT-VERSUS-HOST DISEASE IN MICETransplantation, 1971